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Background
CD8s inhibition of viral replication in vitro was demon-
strated as one of the best laboratory correlates to HIV
control. However, past studies invariably used CD8s which
were rested in vitro for few days before antiviral capacity
examined. This might suggest that the difference between
CD8s from elite controllers (EC) and chronic progressors
(CP) is not in their inhibition capacity but in their ability
to retain cytotoxicity during prolonged incubation. Here
we compared cytotoxicity and apoptosis of CD8s immedi-
ately after their purification (“fresh CD8s”) or 3 days after
in vitro rest (“old CD8s”).
Methods
Samples from 10 EC, 10 CP, 5 HAART treated and 5
HIV negative patients were examined. “Fresh” and “old”
CD8s were used as effectors in viral inhibition assays.
HIV-specific CD8s were quantified using tetramer stain-
ing. Annexin V binding was used to evaluate apoptosis.
Results
Using “old” CD8s inhibition capacity was higher among
EC compared to CP (logP24 reduction 1.225 vs 0.238,
p=0.044). For both EC and CP inhibition was much
stronger using “fresh” CD8s, but no significant difference
was found between EC and CP (logP24 reduction: 3.13 vs
3.85, p=0.29). HIV negative subjects showed no inhibi-
tion using “fresh” or “old” CD8s. IL-2 partially rescued
antiviral capacity of rested CD8s. Loss of HIV-specific
CD8s measured by tetramer staining was higher in CP
compared to EC with up to 10-fold increase in Annexin
V binding.
Conclusion
HIV-specific CD8s from CP are endowed with an unex-
pectedly strong viral inhibition capacity when examined
directly ex vivo. CD8s from EC and CP mediated similar
HIV suppression directly ex vivo, while the superior anti-
viral activity of CD8s from EC after a 3d incubation was
associated with better survival of HIV-specific CD8s. The
capacity to survive and exert effector functions over
extended periods, rather than the intrinsic antiviral capa-
city, best distinguishes CD8s from EC and CP.
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